Clinical Trial Update: Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating pembrolizumab with androgen deprivation therapy and radiotherapy for high-risk localized prostate cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: OHSU Knight Cancer Institute | Conditions: High Risk Prostate Carcinoma, Localized Prostate Adenocarcinoma | Phase 2 | Status: WITHDRAWN